Poolbeg Pharma plc is a biopharmaceutical company dedicated to developing and commercialising innovative medicines that address significant unmet medical needs. The company actively seeks partners for its pipeline of ground-breaking programmes and is open to discussions about partnerships or licensing opportunities.
David Harel, CEO of CytoReason, expressed enthusiasm for the collaboration with Poolbeg Pharma. He stated that the enriched influenza disease model, now enhanced by Poolbeg’s unique data, offers an exciting opportunity to evaluate novel disease mechanisms on CytoReason’s platform. This partnership aims to identify drug targets for developing treatments against influenza, which remains a major global health challenge. Harel highlighted that this approach is expected to achieve results faster and more cost-effectively compared to traditional drug discovery methods.
Similarly, Neel S. Madhukar, CEO of OneThree Biotech, expressed his satisfaction with the collaboration. He noted that using Poolbeg’s unique dataset alongside OneThree’s validated ATLANTIS platform has led to the first AI-driven analysis of RSV disease progression data. Madhukar believes this partnership has delivered actionable insights into disease biology and drug discovery, which could lead to new treatment options for respiratory syncytial virus (RSV), particularly benefiting the young and elderly who are most vulnerable to the infection.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
